Evidence map›Paper›PMID 30430419›Full record

ArticleInternational journal of hematology2019

Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma.

Satoshi Yamasaki, Dai Chihara, Sung-Won Kim, Takahito Kawata, Shuichi Mizuta, Hiroatsu Ago, Takaaki Chou, Takahisa Yamane, Hitoji Uchiyama, Tatsuo Oyake and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Satoshi YamasakiDepartment of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, 1-8-1 Jigyohama, Chuo-Ku, Fukuoka, 810-8563, Japan. yamas009@gmail.com.
Dai ChiharaMedical Oncology Service, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA.
Sung-Won KimDivision of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Takahito KawataDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Shuichi MizutaDepartment of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan.
Hiroatsu AgoDepartment of Hematology and Oncology, Shimane Prefectural Central Hospital, Izumo, Japan.
Takaaki ChouDepartment of Hematology and Oncology, Niigata Cancer Center Hospital, Niigata, Japan.
Takahisa YamaneDepartment of Hematology, Osaka City General Hospital, Osaka, Japan.
Hitoji UchiyamaDepartment of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Tatsuo OyakeDivision of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan.
Katsuhiro MiuraDepartment of Hematology and Rheumatology, Center of Hematoloietic Cell Transplantation and Cell Therapy, Nihon University School of Medicine, Tokyo, Japan.
Bungo SaitoDivision of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Hirofumi TajiDepartment of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan.
Hirohisa NakamaeDepartment of Hematology, Osaka City University Hospital, Osaka, Japan.
Toshihiro MiyamotoHematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
Takahiro FukudaDivision of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Junya KandaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yoshiko AtsutaDepartment of Healthcare Administration, Nagoya University Graduate School of Medicine and Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
Ritsuro SuzukiDepartment of Oncology and Hematology, Shimane University Hospital, Izumo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-dose chemotherapy with autologous stem cell transplantation (HDC-ASCT) is an option for patients with peripheral T-cell lymphoma (PTCL); however, neither prospective nor retrospective studies support proceeding with ASCT upfront, and the timing of HDC-ASCT remains controversial. We retrospectively analyzed the risk factors for outcomes of 570 patients with PTCL, including PTCL not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL), who received ASCT for frontline consolidation (n = 98 and 75, respectively) or alternative therapies after either relapse (n = 112 and 75) or primary induction failure (PIF; n = 127 and 83) between 2000 and 2015. Significant risk factors for overall survival (OS) after upfront ASCT were a ≥ 2 prognostic index for T-cell lymphoma (P < 0.001) and partial response (PR) at ASCT (P = 0.041) in PTCL-NOS patients, and > 60 years of age (P = 0.0028) and PR at ASCT (P = 0.0013) in AITL patients. Performance status of ≥ 2 at ASCT (P < 0.001), receiving ≥ 3 regimens before ASCT (P = 0.018), and PR at ASCT (P = 0.018) in PTCL-NOS patients and > 60 years of age at ASCT (P = 0.0077) in AITL patients were risk factors for OS after ASCT with a chemosensitive PIF status. Strategies that carefully select PTCL patients may allow identification of individuals suitable for ASCT.

Indexed as

AdolescentAdultAgedFemaleHematopoietic Stem Cell TransplantationHumansImmunoblastic LymphadenopathyLymphoma, T-Cell, PeripheralMaleMiddle AgedPatient SelectionRetrospective StudiesRisk FactorsSurvival AnalysisTime FactorsTransplantation, AutologousAngioimmunoblastic T-cell lymphomaAutologous stem cell transplantationPeripheral T-cell lymphoma not otherwise specified

Identifiers

PMID30430419

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.